Clinipace Worldwide, a global digital clinical research organization (dCRO), announced today that it recently closed its best year to date, achieving over 800% revenue growth since 2008. The company more than doubled its revenues in 2010 over the prior year, attributable to 16 new projects awarded from 12 new clients.
“2010 was certainly an exciting year for us”
In addition to conducting several engagements in regulatory consulting, biostatistics and functional monitoring, Clinipace Worldwide was awarded contracts to manage several phase 1, 2 and 3 trials in nephrology/renal, oncology, cardiovascular, and immunology. As a result, the company's hiring rate grew significantly to support increased demand for its technology-amplified services and therapeutic expertise.
Clinipace Worldwide was recognized this past year both regionally and nationally for its tremendous growth with two very prestigious business awards. The company was named to Inc. Magazine's 29th annual Inc. 500, an exclusive ranking of the nation's fastest-growing private companies. This achievement positions Clinipace among the most successful private companies that have experienced substantial revenue growth over a three-year period (2006-2009). Clinipace was also recognized as one of the 50 fastest growing private companies in the Triangle at the Triangle Business Journal's Fast 50 Awards.
"2010 was certainly an exciting year for us," said Jeff Williams, CEO, Clinipace Worldwide. "We're changing the way clinical trials are run - building service solutions on top of a technology platform supported by a team of experts with proven results. To be recognized for this game-changing methodology in the form of new clients and prestigious business awards is a testament to the work our team has done over the past year."
Increased emotional sensitivity linked to previous COVID-19 infection, new research suggests